This is with regards to our intimation made on May 27, 2026 for Press Release wherein there was typographical error in the Subject line of Press Release in the mentioned year, which shall ....
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
FDC Ltd has filed a clarification correcting a typographical error in the subject line of its Q4 FY26 results press release dated May 27, 2026. The company reported strong Q4 FY26 performance with revenue of Rs. 585 crores (up 18.9% Y-o-Y) and EBITDA of Rs. 106 crores (up 97% Y-o-Y) with margins expanding to 18.2% from 11.0%. PAT jumped 167.4% to Rs. 103 crores. For full year FY26, revenue stood at Rs. 2,171 crores (3% growth) with PAT of Rs. 281 crores (5.5% growth). The US Export business delivered exceptional 283.1% growth in Q4 to Rs. 39 crores, while API business grew 38.6% and Domestic Formulations bounced back with 8.5% growth. The company received U.S. FDA approval for Fluconazole Tablets during the quarter.
The typo correction is administrative with no impact on shareholders. However, the underlying Q4 results show exceptional profitability growth with EBITDA margins expanding sharply, which is positive for the stock.